News | News By Subject | News by Disease News By Date | Search News

Multiple myeloma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Patient Deaths Prompt the FDA to Suspend Three of Merck & Co. (MRK)'s Keytruda Trials     7/7/2017
Deaths Force Merck & Co. (MRK) to Halt Enrollment for Blood Cancer Studies     6/14/2017
Unknown Nanjing Legend Emerges as a CAR-T Phenom at ASCO     6/7/2017
Investors Sigh With Relief as bluebird bio (BLUE), Celgene (CELG)'s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free     6/5/2017
This Drug Could be Johnson & Johnson (JNJ)'s Next Billion-Dollar Blockbuster     1/30/2017
bluebird bio (BLUE), Celgene (CELG)'s Multiple Myeloma CAR-T Drug Shines in Tiny Study     12/2/2016
The History Between a Biogen (BIIB) Drug and a High-Profile Democratic Party Fundraiser     10/17/2016
Karyopharm (KPTI) Touts Mid-Stage Data, May See Quicker Approval of Multiple Myeloma Drug     9/6/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon     9/1/2016
Genmab, Inc. (GEN.CO), Johnson & Johnson (JNJ)'s Daratumumab Granted Breakthrough Tag by the FDA     7/26/2016
Amgen (AMGN) Flinches Over Meeting to Review Cost of Multiple Myeloma Drugs     4/7/2016
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement     3/23/2016
Three Drugs Could Catapult Three Big Pharma Revenues This Year     2/9/2016
FDA Grants Full Approval for Amgen (AMGN)'s Blood Cancer Drug     1/25/2016
FDA Approves Takeda (TKPYY)'s Ixazomib for Multiple Myeloma     11/20/2015

News from Around the Web
Amgen (AMGN)’s Backup Plan For Kyprolis Flop     9/30/2016
American Society of Hematology: Secondary Cancers Cloud Myeloma Drug, Roswell Park Cancer Institute Study     12/10/2010
High Response Rates Seen In Phase-III Trial Of Chemotherapy, New Drug And Stem Cells In Myeloma, Azienda Ospedaliera Universitaria San Giovanni Battista of Torino Study     10/14/2010
Possible Genetic Links Between Environmental Toxins And Multiple Myeloma, Bank on a Cure(R) Study     8/14/2009
Treatment With Anti-anemia Drugs May Not Be Safe For Multiple Myeloma Patients, American Journal of Hematology     8/15/2008
One Gene May Be Key to Myeloma, National Cancer Institute Researchers Find     6/24/2008
Blocking a Single Protein Proves Toxic to Myeloma Cells in National Institutes of Health (NIH) Studies     6/23/2008
Three-Drug Combination "Extremely Promising" As First-Line Therapy for Multiple Myeloma, Researchers Say     12/14/2007
New Therapeutic Options for Newly Diagnosed Multiple Myeloma Patients     12/11/2007
Mayo Clinic: Multiple Myeloma Clinical Trial Shows Distinct Survival Benefit with Lower Dose of Steroids     12/10/2007
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity     12/10/2007
Gene Profiling Can Single Out the Worst Cases of Multiple Myeloma and Guide Therapy     9/19/2007
Emory University Researchers Identify Signaling Protein for Multiple Myeloma     9/11/2007
Potential Therapeutic Targets Identified in Multiple Myeloma     8/14/2007
Mayo Clinic Cancer Center Researcher Finds Mold By-product Kills Multiple Myeloma     4/16/2007

Press Releases
PharmaMar Starts A Quadruple Combination Study With Aplidin For The Treatment Of Multiple Myeloma     8/9/2017
Kite Pharma (KITE) Files Key FDA Filing for KITE-585     8/8/2017
New Evidence Of Sutro Biopharma ADC's Potency In Human Tumor Xenografts     7/17/2017
Amgen (AMGN) Release: Second Phase III Study Shows Kyprolis (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma     7/13/2017
Data Presentations At European Hematology Association 22nd Annual Congress Further Validate SkylineDx Prognostic Tools In Multiple Myeloma     6/20/2017
Janssen Biotech (JNJ) Release: DARZALEX (daratumumab) Approved By The U.S. FDA In Combination With Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies     6/19/2017
FDA Accepts Amgen (AMGN)'s Supplemental Biologics License Application To Expand Indication For XGEVA (Denosumab) To Include Multiple Myeloma Patients     6/19/2017
Merck & Co. (MRK) Provides Update On Multiple Myeloma Studies KEYNOTE-183 And 185 Of KEYTRUDA (Pembrolizumab) In Combination With Other Therapies     6/13/2017
Affimed (AFMD) Presents Data On First-In-Class BCMA-Targeting Immune Cell Engager AFM26 At ASCO Annual Meeting 2017     6/6/2017
Amgen (AMGN) Presents New Data From Phase III XGEVA (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017     6/5/2017
Janssen R&D Release: Daratumumab Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma     6/5/2017
Janssen-Cilag International NV (JNJ) Release: Darzalex (Daratumumab) Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma     6/5/2017
Adaptimmune (ADAP) Announces Initiation Of Study To Evaluate SPEAR T-Cell Therapy Targeting NY-ESO In Combination With KEYTRUDA (Pembrolizumab) In Multiple Myeloma     5/25/2017
Genmab A/S (GEN.CO) Announces Plans For New Studies Of Daratumumab     5/18/2017
Glenmark Pharma To Initiate Clinical Study For GBR 1342, Second Investigational New Drug From Immuno-Oncology Portfolio     5/15/2017